Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 8/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48699 | 0.90 | PIK3CD (0.54) | PIK3CDPIK3CAPIK3CGPIK3CBSMN1; SMN2 | |
| SCHEMBL48850 | 0.88 | PIK3CD (0.69) | PIK3CDPIK3CAPIK3CGPIK3CBPI4KB | |
| SCHEMBL48464 | 0.88 | ALDH1A1 (0.53) | PIK3CDPIK3CAPIK3CGPIK3CBSMN1; SMN2 | |
| SCHEMBL48569 | 0.83 | PIK3CG (0.75) | PIK3CDPIK3CAPIK3CGPIK3CBSMN1; SMN2 | |
| SCHEMBL48676 | 0.82 | PIK3CD (0.53) | PIK3CDPIK3CAPIK3CGPIK3CBSMN1; SMN2 | |
| SCHEMBL49803 | 0.77 | PIK3CD (0.66) | PIK3CDPIK3CAPIK3CGPIK3CBPI4KB | |
| SCHEMBL48623 | 0.77 | PIK3CD (0.72) | PIK3CDPIK3CAPIK3CGPIK3CBSMN1; SMN2 | |
| SCHEMBL48491 | 0.76 | PIK3CD (0.64) | PIK3CDPIK3CAPIK3CGPIK3CBNPSR1 | |
| SCHEMBL1784035 | 0.75 | PIK3CD (0.63) | PIK3CDPIK3CAPIK3CGPIK3CBPI4KB | |
| SCHEMBL1784577 | 0.75 | PIK3CD (0.69) | PIK3CDPIK3CAPIK3CGPIK3CBPI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129541-B2 | 5-phenylthiazole derivatives and use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-1480962-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | BRUCE IAN | 2010-04-15 | — | — | US | disclosed |
| US-7687637-B2 | 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors | NOVARTIS AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | NOVARTIS AG (CH) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | PIK3CA, PIK3R5, PIP5K1B | PIK3CD 4/4885PIK3CA 1/4885PIK3CG 8/4885 |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | PIK3CA, PIK3R5, PIP5K1B | PIK3CD 4/4885PIK3CA 1/4885PIK3CG 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.